- Supported exchanges /
- F /
- 8JD.F
VALBIOTIS S.A. EO -10 (8JD F) stock market data APIs
Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
VALBIOTIS S.A. EO -10 Financial Data Overview
1.304 | |
1.304 | |
- | |
1.304 | |
1.304 | |
1.078-6.7 | |
20 848 K | |
15 766 K | |
4 733 K | |
-0.201 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
VALBIOTIS S.A. EO -10 Fundamental Data is available in our Financial Data APIs
- Net Revenue 4 733 K
- EBITDA -6 955 000
- Earnings Per Share -0.65
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get VALBIOTIS S.A. EO -10 Earnings via APIs
- Latest Release 2024-10-29
- EPS/Forecast NaN
Get VALBIOTIS S.A. EO -10 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: